The Shiny–and Potentially Dangerous—New Tool for Predicting Human Behavior

The Shiny–and Potentially Dangerous—New Tool for Predicting Human Behavior

Studies of twins have played an important role in determining that genetic differences play a role in the development of differences in behavior.

(Photo by Jelleke Vanooteghem on Unsplash)


Keep Reading Keep Reading
Eric Turkheimer
Eric Turkheimer is a professor of psychology at the University of Virginia. From 2003 to 2008 he was Director of Clinical Training. Turkheimer has been an Associate Editor for Psychological Assessment, is currently an Associate Editor of Behavior Genetics and has served on the editorial boards of Journal of Personality and Social Psychology and Perspectives on Psychological Science. In 2009, he was awarded the James Shields Memorial Award for outstanding research in Behavioral Genetics. He is a past President of the Behavior Genetics Association. His current research includes detection of G by E interactions in twin studies of intelligence, development of statistical methods for analyses of children of twins, and the use of twins to establish quasi-experimental control in studies of developmental associations between parenting behavior and offspring outcomes in adolescence. His overarching research goal is to explore the possibilities and limitations of behavior genetics as a means of expanding the scope and rigor of human behavioral science.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.